• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.

作者信息

Ambrosio Maria R, Lazzi Stefano, Bello Giuseppe Lo, Santi Raffaella, Porro Leonardo Del, de Santi Maria M, Guazzo Raffaella, Mundo Lucia, Rigacci Luigi, Kovalchuck Sofia, Onyango Noel, Fabbri Alberto, Cencini Emanuele, Zinzani Pier Luigi, Zaja Francesco, Angrilli Francesco, Stelitano Caterina, Cabras Maria G, Spataro Giuseppe, Bob Roshanak, Menter Thomas, Granai Massimo, Cevenini Gabriele, Naresh Kikkeri N, Stein Harald, Sabattini Elena, Leoncini Lorenzo

机构信息

Department of Medical Biotechnologies, University of Siena, Italy.

Division of Pathological Anatomy, University of Florence, Italy.

出版信息

Haematologica. 2019 Jan;104(1):e25-e28. doi: 10.3324/haematol.2018.195958. Epub 2018 Jun 28.

DOI:10.3324/haematol.2018.195958
PMID:29954940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6312021/
Abstract
摘要

相似文献

1
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.MYC蛋白表达评分及其对侵袭性B细胞淋巴瘤患者预后的影响。
Haematologica. 2019 Jan;104(1):e25-e28. doi: 10.3324/haematol.2018.195958. Epub 2018 Jun 28.
2
Inferior survival in high-grade B-cell lymphoma with and and/or rearrangements is not associated with gene rearrangements.伴有 和/或 重排的高级别 B 细胞淋巴瘤患者的生存情况较差，但与 基因重排无关。
Haematologica. 2018 Nov;103(11):1899-1907. doi: 10.3324/haematol.2018.190157. Epub 2018 Jun 14.
3
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.在接受 6 个周期 CHOP 治疗的侵袭性 B 细胞淋巴瘤患者中，使用利妥昔单抗 6 或 8 个剂量：来自“侵袭性非霍奇金淋巴瘤正电子发射断层扫描引导治疗”（PETAL）试验的结果。
Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4.
4
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.在德国高级非霍奇金淋巴瘤研究组的前瞻性临床试验中，针对弥漫性大 B 细胞淋巴瘤进行治疗，探讨了细胞起源分类和 MYC/BCL2 双表达状态的临床影响。
J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19.
5
MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.MYC 和 BCL2 蛋白表达可预测接受利妥昔单抗治疗的弥漫性大 B 细胞淋巴瘤患者的生存情况。
Br J Haematol. 2014 May;165(3):382-91. doi: 10.1111/bjh.12763. Epub 2014 Feb 8.
6
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.双打击基因表达特征定义了生发中心 B 细胞样弥漫性大 B 细胞淋巴瘤的一个独特亚群。
J Clin Oncol. 2019 Jan 20;37(3):190-201. doi: 10.1200/JCO.18.01583. Epub 2018 Dec 3.
7
Differential therapy for diffuse large B-cell lymphoma with different cells of origin.针对不同起源细胞的弥漫性大B细胞淋巴瘤的差异化治疗。
Onkologie. 2009 Dec;32(12):711-2. doi: 10.1159/000258134. Epub 2009 Nov 19.
8
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.来那度胺联合剂量调整的 EPOCH-R 方案治疗 MYC 和 BCL2 失调的侵袭性 B 细胞淋巴瘤的 1 期研究。
Cancer. 2019 Jun 1;125(11):1830-1836. doi: 10.1002/cncr.31877. Epub 2019 Feb 1.
9
Prognostic Significance of Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.弥漫性大 B 细胞淋巴瘤中重排和易位伙伴的预后意义：Lunenburg 淋巴瘤生物标志物联盟的研究。
J Clin Oncol. 2019 Dec 10;37(35):3359-3368. doi: 10.1200/JCO.19.00743. Epub 2019 Sep 9.
10
Rituximab plus CHOP for diffuse large-B-cell lymphoma.利妥昔单抗联合CHOP方案治疗弥漫性大B细胞淋巴瘤
N Engl J Med. 2002 Jun 6;346(23):1830-1; author reply 1830-1. doi: 10.1056/NEJM200206063462317.

引用本文的文献

1
A Diagnostic Approach in Large B-Cell Lymphomas According to the Fifth World Health Organization and International Consensus Classifications and a Practical Algorithm in Routine Practice.根据世界卫生组织第五版和国际共识分类对大B细胞淋巴瘤的诊断方法及常规实践中的实用算法
Int J Mol Sci. 2024 Dec 9;25(23):13213. doi: 10.3390/ijms252313213.
2
Combined immunohistochemical profile CD10/LMO2/MYC is a useful tool to screen MYC rearrangements in aggressive large B-cell lymphomas.联合免疫组化谱CD10/LMO2/MYC是筛查侵袭性大B细胞淋巴瘤中MYC重排的有用工具。
Virchows Arch. 2025 May;486(5):951-959. doi: 10.1007/s00428-024-03945-y. Epub 2024 Oct 22.
3
C-MYC-activated lncRNA SNHG20 accelerates the proliferation of diffuse large B cell lymphoma via USP14-mediated deubiquitination of β-catenin.C-MYC 激活的长链非编码 RNA SNHG20 通过 USP14 介导的β-连环蛋白去泛素化加速弥漫性大 B 细胞淋巴瘤的增殖。
Biol Direct. 2024 Jun 18;19(1):47. doi: 10.1186/s13062-024-00488-9.
4
C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.C-Myc 蛋白表达预示手术切除的小细胞肺癌患者临床结局不佳。
World J Surg Oncol. 2024 Feb 19;22(1):57. doi: 10.1186/s12957-024-03315-7.
5
Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.弥漫性大 B 细胞淋巴瘤中的非 IG::MYC 具有可变的基因组结构和 MYC 转录激活潜能。
Leukemia. 2024 Mar;38(3):621-629. doi: 10.1038/s41375-023-02134-1. Epub 2024 Jan 6.
6
MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B-cell lymphoma patients.MYC过表达而非MYC/BCL2双重表达可预测大包块弥漫性大B细胞淋巴瘤患者的生存情况。
Cancer Med. 2023 Sep;12(18):18568-18577. doi: 10.1002/cam4.6463. Epub 2023 Aug 28.
7
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.免疫微环境的遗传亚型和表型特征以及 MYC/BCL2 双表达揭示弥漫性大 B 细胞淋巴瘤的异质性。
Clin Cancer Res. 2022 Mar 1;28(5):972-983. doi: 10.1158/1078-0432.CCR-21-2949.
8
The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.弥漫性大B细胞淋巴瘤患者中MYC和BCL2双重表达的发生率及治疗反应：一项系统评价和荟萃分析
Cancers (Basel). 2021 Jul 5;13(13):3369. doi: 10.3390/cancers13133369.
9
Risk Stratification Using Multivariable Fractional Polynomials in Diffuse Large B-Cell Lymphoma.使用多变量分数多项式对弥漫性大B细胞淋巴瘤进行风险分层
Front Oncol. 2020 Mar 11;10:329. doi: 10.3389/fonc.2020.00329. eCollection 2020.
10
Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases.MYC 蛋白阴性伯基特淋巴瘤病例中从 MYC 到 MYCN 表达的分子开关。
Blood Cancer J. 2019 Nov 20;9(12):91. doi: 10.1038/s41408-019-0252-2.

本文引用的文献

1
High-grade B-cell lymphoma with and and/or rearrangements with diffuse large B-cell lymphoma morphology.伴有 和/或 重排的高级别 B 细胞淋巴瘤，伴弥漫性大 B 细胞淋巴瘤形态学特征。
Blood. 2018 May 3;131(18):2060-2064. doi: 10.1182/blood-2017-12-820605. Epub 2018 Feb 23.
2
Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation.双表达型淋巴瘤患者在接受异基因造血细胞移植后预后不良。
Biol Blood Marrow Transplant. 2018 Feb;24(2):294-300. doi: 10.1016/j.bbmt.2017.10.013. Epub 2017 Oct 14.
3
How I treat double-hit lymphoma.我是如何治疗双打击淋巴瘤的。
Blood. 2017 Aug 3;130(5):590-596. doi: 10.1182/blood-2017-04-737320. Epub 2017 Jun 9.
4
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.在德国高级非霍奇金淋巴瘤研究组的前瞻性临床试验中，针对弥漫性大 B 细胞淋巴瘤进行治疗，探讨了细胞起源分类和 MYC/BCL2 双表达状态的临床影响。
J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19.
5
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.复发或难治性双表达和双打击淋巴瘤在自体干细胞移植后的无进展生存期较差。
J Clin Oncol. 2017 Jan;35(1):24-31. doi: 10.1200/JCO.2016.68.2740. Epub 2016 Oct 24.
6
High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.伴有MYC和BCL2及/或BCL6重排的高级别B细胞淋巴瘤：双打击和三打击淋巴瘤以及双表达淋巴瘤。
Blood Rev. 2017 Mar;31(2):37-42. doi: 10.1016/j.blre.2016.09.004. Epub 2016 Sep 30.
7
MYC and BCL2 evaluation in routine diagnostics of aggressive B-cell lymphomas - presentation of a work-flow and the experience with 248 cases.MYC和BCL2评估在侵袭性B细胞淋巴瘤常规诊断中的应用——工作流程介绍及248例病例经验
Br J Haematol. 2017 Nov;179(4):681-684. doi: 10.1111/bjh.14250. Epub 2016 Jul 22.
8
MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.在临床实践中通过MYC免疫组织化学鉴定MYC驱动的B细胞淋巴瘤
Am J Clin Pathol. 2016 Feb;145(2):166-79. doi: 10.1093/ajcp/aqv028. Epub 2016 Feb 1.
9
Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.双打击和双蛋白表达淋巴瘤：侵袭性和难治性淋巴瘤。
Lancet Oncol. 2015 Nov;16(15):e555-e567. doi: 10.1016/S1470-2045(15)00005-4.
10
Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.MYC与BCL2蛋白共表达在接受二线免疫化疗的侵袭性B细胞淋巴瘤中的临床意义
Leuk Lymphoma. 2016;57(6):1335-41. doi: 10.3109/10428194.2015.1096352. Epub 2015 Oct 22.